← Back to Clinical Trials
Recruiting NCT05646732

NCT05646732 Targeting the Default Mode Network: A TMS-fMRI Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05646732
Status Recruiting
Phase
Sponsor Allyson Rosen
Condition Post Traumatic Stress Disorder
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2023-08-02
Primary Completion 2025-01-31

Trial Parameters

Condition Post Traumatic Stress Disorder
Sponsor Allyson Rosen
Study Type INTERVENTIONAL
Phase N/A
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age 55 Years
Start Date 2023-08-02
Completion 2025-01-31
Interventions
TMS-fMRI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

In post-traumatic stress disorder (PTSD), intrusive, traumatic, autobiographical memories lead to anxiety symptoms. Recent work suggests a new repetitive pulse transcranial magnetic stimulation (rTMS) brain target that might bring relief. Since this proposed target is not well understood, the goal of the study is to use functional magnetic resonance imaging (fMRI) to identify the brain regions and networks that change with rTMS stimulation at this target area in PTSD patients. Ultimately, this would lead to a personalized approach to rTMS treatment of PTSD based on brain imaging that can be used in a future clinical trial. Participants will be asked to complete psychological testing and questionnaires as well as an initial MRI and two separate TMS-fMRI sessions. Total participation time across all visits is estimated to be five to six hours. Research participation will take place at VA Palo Alto as well as at Stanford University.

Eligibility Criteria

Inclusion Criteria: * Between 18 and 55 years of age * Ability to maintain a Motor Threshold (MT) with single pulse TMS * Ability to safely and comfortably undergo an MRI and TMS * Able to read, verbalize, understand, and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments. * PTSD diagnosis according to the DSM 5, as determined by the Clinician administered PTSD scale (CAPS-5) criteria. * Commitment to maintaining a stable medication regimen between the two fMRI sessions Exclusion Criteria: * Inability to safely and comfortably undergo an MRI. MRI safety will be determined by the center where MRI's are collected. * Inability to safely and comfortably undergo TMS. TMS exclusions include any history or condition that puts patients at risk. * Significant dementia as determined by the Montreal Cognitive Assessments (MoCA) * Common comorbid disorders of Veterans are allowed, but PTSD must be a primary diagnosis causing significan

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology